Anavex Life Sciences Receives FDA Feedback on Alzheimer's Disease Program GlobeNewswire January 06, 2026 NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, […]

Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair GlobeNewswire January 06, 2026 WALTHAM, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has elected Dr. Martin D. Madaus as Chair of the Board, effective March

BullFrog AI-Driven Precision Oncology Analytics Identifies 3x Increase in Overall Survivability in Patient Subgroups through Key Biomarkers in Pancreatic Cancer Company's bfLEAP(R) platform successfully identified treatment effect heterogeneity and possible early predictors of outcomes in pancreatic cancer in data to be presented at ASCO GI GlobeNewswire January 06, 2026 GAITHERSBURG, Md., Jan. 06, 2026 (GLOBE

SL Green and Rockpoint Announce Joint Venture for Ownership of 100 Park Avenue GlobeNewswire January 06, 2026 NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) — SL Green Realty Corp. (NYSE:SLG), Manhattan's largest office landlord, and Rockpoint, a Boston-based real estate private equity firm, today announced a joint venture for the ownership of 100 Park Avenue

Habit Brings Back Gotta Habit Meal Deals Fan demand brings back Habit's $6, $8 and $10 Gotta Habit Meal Deals, featuring bold flavor and fresh ingredients at unbeatable value GlobeNewswire January 06, 2026 IRVINE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) — When guests ask, Habit answers. Thanks to overwhelming demand, Habit is bringing back its

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 06, 2026 WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that ProKidney's CEO, Bruce Culleton, M.D., will present at

Bread Financial Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call for Jan. 29 GlobeNewswire January 06, 2026 COLUMBUS, Ohio, Jan. 06, 2026 (GLOBE NEWSWIRE) — Bread Financial(R) Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions will host a conference call on Thursday, Jan.

Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025's Significant Achievements and Outlining Upcoming Milestones for 2026 GlobeNewswire January 06, 2026 SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company's Platform Seeks to Address an Estimated $30+ Billion Global KRAS-Driven Cancer Market with Pan-KRAS

Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 06, 2026 DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday,

Atsena Therapeutics Appoints McDavid Stilwell as Chief Financial Officer GlobeNewswire January 06, 2026 Seasoned biotech executive brings over 25 years of leadership experience across financial strategy and operations, investor relations and business development DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) — Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of